External reports (aggregated public sources), Value Investors Club

Value Investors Club

External reports (aggregated public sources)

Equity Bottom-Up

<ul><li>Abeona is developing a cell therapy for the rare disease RDEB, with FDA review ongoing and a target action date of May 25th</li><li>The therapy is expected to have a significant impact on RDEB patients, who face severe skin and GI issues due to a lack of specific collagen</li><li>With a niche business model focused on treating a small patient population, Abeona anticipates generating over $100 million in free cash flow and potentially offering significant upside for investors.</li></ul><p><em>This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.</em></p>

Abeona is developing a cell therapy for the rare disease RDEB, with FDA review ongoing and a target action date of May 25thThe therapy is expected to have a significant impact on RDEB patients, who face severe skin and GI issues due to a lack of specific collagenWith a niche business model focused on treating a small patient population, Abeona anticipates generating over $100 million in free cash flow and potentially offering significant upside for investors.This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Abeona Therapeutics Inc (ABEO) - Thursday, Feb 15, 2024

United States

Abeona Therapeutics Inc. is a leading clinical-stage biopharmaceutical company. The Company develops novel gene therapies for life-threatening rare diseases.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00